What is the ticker symbol for Cellectis S.A.?

Cellectis S.A. trades under the ticker CLLS on NASDAQ.

What sector does Cellectis S.A. operate in?

Cellectis S.A. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CLLS in a portfolio?

PortView shows CLLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Cellectis S.A. (CLLS) Stock Analysis

NASDAQHealthcareBiotechnology

$3.22-2.42%

1-year price historyRange $2.59 – $5.35

52-week range$3.22

$2.35$5.48

What Cellectis S.A. does

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.

Key metrics

Market cap

$323.34M

P/E (TTM)

-4.81

EPS (TTM)

$-0.67

Beta

2.90

Dividend yield

0.00%

Revenue / share

$0.56

50-day avg

$2.99

200-day avg

$3.70

52-week high

$5.48

52-week low

$2.35

CEO

Andre Choulika

ETFs linked to CLLS

Broad-market and Healthcare sector ETFs an investor holding Cellectis S.A. is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how CLLS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CLLS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Cellectis S.A.?: Cellectis S.A. trades under the ticker CLLS on NASDAQ.
Which exchange is CLLS listed on?: CLLS is listed on NASDAQ.
What sector does Cellectis S.A. operate in?: Cellectis S.A. is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CLLS in a portfolio?: PortView shows CLLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.